Control BionicsASX:CBL -5.13% EV-to-FCF is -5.97 as of Jul. 01, 2026. The stock has 6 warning signs investors should review. Among 419 Medical Devices & Instruments companies, Control Bionics ranks worse than 238663.25% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Control Bionics's Enterprise Value is A$27.67 Mil.
Control Bionics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.64 Mil. Therefore, Control Bionics's EV-to-FCF for today is -5.97.
The historical rank and industry rank for Control Bionics's EV-to-FCF or its related term are showing as below:
ASX:CBL'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.27 Med: -1.71 Max: 1.11
Current: -6.68
During the past 6 years, the highest EV-to-FCF of Control Bionics was 1.11. The lowest was -8.27. And the median was -1.71.
ASX:CBL's EV-to-FCF is ranked worse than 100% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.57
vs ASX:CBL: -6.68
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Control Bionics's PE Ratio (TTM) for today is calculated as:
Control Bionics's share price for today is A$0.074.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Control Bionics EV-to-FCF Related Terms
Control Bionics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Control Bionics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Control Bionics's EV-to-FCF falls into.
Control Bionics's current Enterprise Value is A$27.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a EV-to-FCF of -5.97 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #999999 out of 419 companies in the Medical Devices & Instruments industry.
Is Control Bionics' EV-to-FCF too high?
Control Bionics' current EV-to-FCF is -5.97. Based on the distribution chart, Control Bionics ranks #999999 out of 419 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Control Bionics' EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #999999 out of 419 companies for EV-to-FCF. This places Control Bionics in the lower half of its industry. The industry median EV-to-FCF is 22.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.57, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current EV-to-FCF is -5.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 146.7% above its estimated fair value. The current EV-to-FCF is -5.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current EV-to-FCF is -5.97 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 